Latest Health News

AVITA Medical has appointed Board Chairman Cary Vance as Interim CEO following Jim Corbett's departure, while preliminary third-quarter revenue is expected to reach approximately $17 million.

Biome Australia Limited has reported a record quarterly revenue of $5.94 million for Q1 FY26, marking a 40% increase year-over-year and its seventh consecutive quarter of positive EBITDA. The company’s strong cash flow and sustained margins underscore its growth momentum.

Fiducian Group Limited has voluntarily released its Appendix 4C for Q3 2025, reporting steady net inflows to its core platform and a rise in total funds under management to $15.6 billion.

Alcidion Group Limited has reported a record FY25 with strong revenue growth, major NHS contract wins, and expanded AI capabilities in its Miya Precision platform, setting the stage for global healthcare IT expansion.

Mayne Pharma’s planned acquisition by Cosette Pharmaceuticals faces a delay as the Foreign Investment Review Board postpones its decision, potentially pushing back key court proceedings.

PainChek Limited has confirmed FDA De Novo classification for its PainChek Adult App, promptly disclosing the material regulatory milestone to the ASX and signalling a significant step towards US market entry.

Health Canada has requested additional information, extending its review of CLINUVEL’s SCENESSE® for erythropoietic protoporphyria (EPP) into 2026. Meanwhile, Canadian patients continue to access the treatment via a Special Access Program.

Oliver’s Real Food Limited reported a striking turnaround in its September 2025 quarter, with EBIT soaring 192% and operating cash flow swinging positive despite a dip in overall revenue.

TrivarX Limited has announced the acquisition of Stabl-Im, a novel stable isotope MRI technology for early brain tumor detection, backed by a $4.2 million capital raise including investment from biotech leader Dr Daniel Tillett.

Mayne Pharma has won a key legal battle against Cosette Pharmaceuticals, clearing the way for its acquisition scheme to proceed pending final approvals. Shareholders can expect the deal to move forward with payments scheduled soon.

Bannerman Energy reports solid progress at its Etango Uranium Project, securing initial offtake agreements and maintaining robust financial health as it targets a Final Investment Decision within the next year.

Bannerman Energy Ltd reported a robust cash position of AUD 111.76 million at the end of September 2025, underpinning an estimated 13.5 quarters of operational funding despite ongoing exploration expenditures.